Vilastobart in combination with atezolizumab continued to demonstrate a differentiated and generally well-tolerated safety profile. Treatment-related adverse events (AEs) were primarily Grade 1 or 2, ...

Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a ...

Jay will begin with a review of recent corporate updates and discuss our clinical programs for DuraVu in wet AMD and DME.

ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) Estimate 55% of patients with MSS CRC have high plasma TMB, representing ...

NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) ("WeightWatchers,” "WW,” or the "Company”) today announced its results for the third quarter of fiscal 2025 ended ...

Cynata Therapeutics Limited ( OTCPK:CYYNF) Discusses Clinical Trial Progress and Corporate Developments Including GVHD, Osteoarthritis, and Kidney Transplantation November 5, 2025 8:30 PM EST ...

Q3 2025 Earnings Call Transcript November 3, 2025 BioNTech SE misses on earnings expectations. Reported EPS is $-0.14 EPS, ...

Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a previously announced debt-facility, are expected to pr ...

Callan, a leading institutional investment consulting firm, announced the release of its 2025 Asset Manager Sustainable Investment Practices Study, highlighting asset manager responses to ...

Q3 2025 Earnings Call Transcript November 4, 2025 CeriBell, Inc. beats earnings expectations. Reported EPS is $-0.37, expectations were $-0.43. Operator: Good afternoon, and thank you all for ...

Snowflake , the AI Data Cloud company, today announced innovations that make it easier for organizations to ingest, access, and govern their data across the entire data lifecycle, redefining the ...